4dmedical Ltd. · ASX:4DX
4dmedical — Investor Presentation (January 2026)
20 slides from 4dmedical's investor presentation, Jan 19, 2026
Slide 1: Investor Presentation
4DMedical Limited (ASX:4DX) Investor Presentation 19 January 2026 For personal use only See beyond the structure Copyright © 4DMedical Limited 2026 Level 7, Melbourne Connect 700 Swanston Street Melbourne, Victoria 3053 Australia ABN 31 161 684 831 www.4dmedical.com
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (Company or 4DMedical). This presentation contains summary information about the Company, its subsidiaries and the entities, businesses and assets they own and operate (Group) and their activi
Slide 3: Who is 4DMedical?
Who is ? For personal use only The leading pulmonary & Structural & Functional Imaging software cardiothoracic imaging software company in the market 100+ patented technologies 9 FDA cleared devices 4DMedical was founded in Melbourne in 2013 to bring breakthrough lung function imaging 130 global tea
Slide 4: Portfolio
Portfolio Pulmonary Function Pulmonary Structure Cardiovascular For personal use only XV LVAS® Lung Density CAC Dynamic Ventilation Analysis (Fluoro) Emphysema, HAA, Fissures Coronary Calcification CT LVAS Lung Texture PHA CT-based Ventilation Analysis ILD’s / Fibrosis Hypertension (RV/LV, MPA, Pa/A
Slide 5: All the CONTRAST. None of the INJECTIONS.
All the CONTRAST. None of the INJECTIONS. Value-adding the standard-of-care Chest CTs with non-contrast functional imaging For personal use only + Software layer CT:VQ Non-contrast Ventilation & Perfusion Routine CT Clinical Value 5 4DMedical Limited (ASX:4DX) January 2026
Slide 6: Standard-of-care for VQ imaging in the U.S.
Standard-of-care for VQ imaging in the U.S. For personal use only 2/3 of US market still uses 2D / ‘planar scintigraphy’ for VQ scans Planar Ventilation & Perfusion V Q 6 4DMedical Limited (ASX:4DX) January 2025
Slide 7: Mismatch of Perfusion and Ventilation (SPECT V/Q and CT:VQ)
Mismatch of Perfusion and Ventilation (SPECT V/Q and CT:VQ ) CT:VQ delivers increased image quality directly from the routine CT: For personal use only • without the additional imaging procedure and without injected contrast Routine HRCT CT:VQ Non-Contrast Ventilation & Perfusion V Q 7 4DMedical Lim
Slide 8: CT:VQ opportunity
CT:VQ opportunity ✓ Transformational Milestone: For personal use only ✓ CT:VQ becomes the world’s first and only non-contrast, CT-based ventilation-perfusion imaging technology to receive FDA 510(k) clearance. ✓ Large Addressable Market: ✓ Over 1M VQ scans annually in the U.S.; USD $1.1B+ U.S. marke
Slide 9: CT:VQ to take 100% market share
CT:VQ to take 100% market share Patient Value For personal use only Reasons to change ✓ Improved patient comfort Referring Doctor Value ✓ Shorter scan times and ✓ Uses existing CT they order appointments anyway ✓ Ubiquitous access to perfusion ✓ Confidence in scheduling due to analysis shorter wait
Slide 10: Revenue generation | cost reduction | opportunity costs
Revenue generation | cost reduction | opportunity costs CT:VQ vs Nuclear V/Q | Nuclear V/Q vs Cardiac Molecular Imaging Shift to CT:VQ Current Nuclear VQ Alternate Nuclear study example For personal use only CT Thorax (non-contrast) with CT:VQ Nuclear V/Q (Xe133 & Tc99m) Myocardial PET stress CPT Co
Slide 11: Philips CT:VQ expansion
Philips CT:VQ expansion • Agreement for CT:VQ across North America For personal use only – Expands on existing agreement to add CT:VQ with minimum orders commitment over 2-year term – Supported by additional Philips business development, sales and clinical specialist resources – Joint marketing init
Slide 12: Philips and VA opportunity
Philips and VA opportunity Combined capabilities to build a compelling offer for ‘owning the lung’ and shared purpose For personal use only Why Philips partner with 4DMedical – the Veterans Affairs opportunity Why does VA need to act? rationale ➢ The U.S. PACT Act has appropriated USD $280b ➢ 4DMedi
Slide 13: Unstoppable momentum in US AMCs
Unstoppable momentum in US AMCs For personal use only Strategy for adoption at top-tier, influential, U.S. academic medical centres and health systems Top 20 US Hosp - Interventional Pulmonology 1 Top 20 – US Hospitals * Active Future opportunity Active Future opportunity CT:VQ contracted 15% 85% CT
Slide 14: Built the fundamentals, significant multipliers in play, Philips commitments
Built the fundamentals, significant multipliers in play, Philips commitments • Technology validated For personal use only – 100+ patents, 9 FDA cleared products, numerous academic publications • Proven – products: full pulmonary imaging suite • with CT:VQ the key unrivalled disruptor as a replacemen
Slide 15: Institutional Placement
For personal use only Institutional Placement 4DMedical Limited (ASX:4DX) January 2026
Slide 16: AU$150M Institutional Placement
AU$150M Institutional Placement For personal use only Overview • Bell Potter Securities Limited were the Lead Managers of the Placement • Successfully raised AU$150 million via a single-tranche institutional placement at $3.80 per share • Strong demand from new global long-only fund managers and exi
Slide 17: Use of funds
Use of funds For personal use only Focused investment to drive adoption of CT:VQ Proceeds will be used to: • Accelerate U.S. commercialisation of CT:VQ – Sales, marketing and business development – Expansion across academic medical centres and health systems • Invest in customer success and clinical
Slide 18: 4DMedical raises $150 million, limiting dilution to 3.86%
4DMedical raises $150 million, limiting dilution to 3.86% New issue For personal use only Alpha (“Block”) (“Placement”) 18,677,500 20,806,185 519,673,787 = 538,351,287 559,157,472 Ordinary Total Ordinary 3.86% Dilution shares Ordinary shares shares $150m cash On issue prior to Placement, held by 4DM
Slide 19: Placement Timetable
Placement Timetable For personal use only Trading halt Tuesday, 13 January 2026 Placement opens Tuesday, 13 January 2026 Placement closes Wednesday, 14 January 2026 Capital raising results announced and trading halt lifted Thursday, 15 January 2026 Settlement of New Shares via DVP Wednesday, 21 Janu
Slide 20: 4DMedical Limited contact details
For personal use only 4DMedical Limited (ASX:4DX) 19 January 2026 Copyright © 4DMedical Limited 2026 Level 7, Melbourne Connect 700 Swanston Street Melbourne, Victoria 3053 Australia www.4dmedical.com ABN 31 161 684 831